DENVER--(BUSINESS WIRE)--Ceragenix Pharmaceuticals, Inc. (OTCBB:CGXP), a biopharmaceutical company focused on infectious disease and dermatology, today announced that a catheter treated with a Ceragenin compound demonstrated virtually no biofilm formation in a 21 day study.
